Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 294

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

A Randomized Trial of Clarithromycin as Prophylaxis against Disseminated Mycobacterium avium Complex Infection in Patients with Advanced Acquired Immunodeficiency Syndrome

Open access
Pierce, Mark, Crampton, Sheri, Henry, David, Heifets, Leonid, LaMarca, Anthony, Montecalvo, Marisa, Wormser, Gary P., Jablonowski, Helmut, Jemsek, Joseph, Cynamon, Michael, Yangco, Bienvenido G., Notario, Gerard, Craft, J Carl·1996·New England Journal of Medicine
DOI 10.1056/nejm199608083350603
Open this paper in CoChat — free account

Abstract

BACKGROUND: Disseminated infection with Mycobacterium avium complex is the most common opportunistic infection in patients with advanced stages of the acquired immunodeficiency syndrome (AIDS). We studied the efficacy and safety of prophylactic treatment with clarithromycin, a macrolide antibiotic. METHODS: We conducted a randomized, placebo-controlled, double-blind study of clarithromycin in patients with AIDS in the United States and Europe. Entry criteria included blood cultures that were negative for M. avium complex, a Karnofsky performance score of 50 or higher, a CD4 cell count of 100 or less per cubic millimeter, and a life expectancy of at least six months. RESULTS: After the first interim analysis, the study was stopped. M. avium complex infection developed in 19 of the 333 patients (6 percent) assigned to clarithromycin and in 53 of the 334 (16 percent) assigned to placebo (adjusted hazard ratio, 0.31; 95 percent confidence interval, 0.18 to 0.53; P<0.001). During the follow-up period of about 10 months, 32 percent of the patients in the clarithromycin group died and 41 percent of those in the placebo group died (hazard ratio, 0.75; P=0.026). In the clarithromycin group, isolates from 11 of the 19 patients with M. avium complex infection were resistant to clarithromycin. Prophylaxis with clarithromycin was associated with an increased incidence of taste perversion (11 percent in the clarithromycin group vs. 2 percent in the placebo group, P<0.001) and rectal disorders (8 percent vs. 3 percent, P = 0.007); however, the frequency of more severe adverse events was similar in the two groups (7 percent and 6 percent, respectively). CONCLUSIONS: In patients with advanced AIDS, the prophylactic administration of clarithromycin is well tolerated, prevents M. avium complex infection, and reduces mortality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199608083350603

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 294

Metadata

Authors
Pierce, M., Crampton, S., Henry, D., Heifets, L., LaMarca, A., Montecalvo, M., Wormser, G. P., Jablonowski, H., Jemsek, J., Cynamon, M., Yangco, B. G., Notario, G., & Craft, J. C.
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
1996-08-08
Volume
335
Issue
6
Pages
384-391
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejm199608083350603
OpenAlex
W2338479447
Cited by
294
References
12
FWCI
37.01
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Randomized Trial of Clarithromycin as Prophylaxis against Disseminated Mycobacterium avium Complex Infection in Patients with Advanced Acquired Immunodeficiency Syndrome. https://app.cochat.ai/papers/10.1056/nejm199608083350603
The paper
Pierce, M., Crampton, S., Henry, D., Heifets, L., LaMarca, A., Montecalvo, M., Wormser, G. P., Jablonowski, H., Jemsek, J., Cynamon, M., Yangco, B. G., Notario, G., & Craft, J. C. (1996). A Randomized Trial of Clarithromycin as Prophylaxis against Disseminated Mycobacterium avium Complex Infection in Patients with Advanced Acquired Immunodeficiency Syndrome. New England Journal of Medicine. https://doi.org/10.1056/nejm199608083350603

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.